Using phase II data for the analysis of phase III studies: an application in rare diseases

Simon Wandel¹,*, Beat Neuenschwander¹, Christian Röver², and Tim Friede²

¹Novartis Pharma AG, Basel, Switzerland
²Department of Medical Statistics, University Medical Center Göttingen, Humboldtallee 32, 37073 Göttingen, Germany

Short title: Using phase II data in phase III

Word count (excluding formulas, tables, figures): 3578

Funding: This research has received funding from the EU’s 7th Framework Programme for research, technological development and demonstration under grant agreement number FP HEALTH 2013-602144 with project title (acronym) "Innovative Methodology for Small Populations Research" (InSPiRe).

*Corresponding author: Simon Wandel, Novartis Pharma AG, Basel
Abstract

Background
Clinical research and drug development in orphan diseases is challenging, since large-scale randomized studies are difficult to conduct. Formally synthesizing the evidence is therefore of great value, yet this is rarely done in the drug approval process. Phase III designs that make better use of phase II data can facilitate drug development in orphan diseases.

Methods
A Bayesian meta-analytic approach is used to inform the phase III study with phase II data. It is particularly attractive, since uncertainty of between-trial heterogeneity can be dealt with probabilistically, which is critical if the number of studies is small. Furthermore, it allows quantifying and discounting the phase II data through the predictive distribution relevant for phase III. A phase III design is proposed which uses the phase II data and considers approval based on a phase III interim analysis. The design is illustrated with a non-inferiority case study from an FDA approval in herpetic keratitis (an orphan disease). Design operating characteristics are compared to those of a traditional design, which ignores the phase II data.

Results
An analysis of the phase II data reveals good but insufficient evidence for non-inferiority, highlighting the need for a phase III study. For the phase III study supported by phase II data, the interim analysis is based on half of the patients. For this design, the meta-analytic interim results are conclusive and would justify approval. In contrast, based on the phase III data only, interim results are inconclusive and would require further evidence.

Conclusions
To accelerate drug development for orphan diseases, innovative study designs and appropriate methodology are needed. Taking advantage of randomized phase II data when analyzing phase III studies looks promising because the evidence from phase II supports informed decision making. The implementation of the Bayesian design is straightforward with public software such as R.

Keywords: drug development in rare diseases; phase III studies; Bayesian statistics; meta-analysis
Introduction

Clinical research in orphan diseases is challenging. It is often impossible or unethical to conduct large scale randomized controlled trials, which implies that only limited evidence is available for decision making. Also, shortcomings in the methodological approaches to evaluate medical products in rare diseases have been identified (e.g. Unkel et al [1]). Whilst these problems have been recognized for some time (see Orphan Drug Act from 1983 [2]), only in the past few years strong efforts have been made to address them. Examples include the draft guidance by the Food and Drug Administration (FDA) for drug development in rare diseases [3] and the latest funding scheme for rare diseases by the European Union’s Horizon 2020 research program [4]. These activities have led to intensified rare diseases research and drug development by pharmaceutical companies [5].

With regards to the drug approval process, some flexibility on study designs and endpoints has been observed for drugs with an orphan indication [6, 7]. Surprisingly, however, a formal combination of the evidence (for example a meta-analysis) is rarely presented in approval dossiers. Typically, efficacy is assessed based on confirmatory trials only, meaning that other evidence (such as phase II studies) is viewed as supportive only. This poses a problem to both, regulators in charge of approving drugs and companies developing them, since it limits the evidence base for a quantitative assessment of the treatment effect. Furthermore, the combination of data reveals its power particularly in situations with limited data at hand, which is often the case for rare diseases.

These challenges call for approaches to study design and analysis that allow a more efficient use of the available data, as stipulated e.g. in the 21st Century Cures Act [8]. The nature of the problem lends itself to the Bayesian approach. The usefulness of the Bayesian approach when meta-analyzing few (small) studies has been discussed elsewhere (see Friede et al [9, 10]). Here, we extend the idea to incorporate existing evidence for the parameter of interest, the treatment effect corresponding to the phase III study, via a meta-analysis. This is based on concepts discussed by Spiegelhalter et al [11], Neuenschwander et al [12, 13], Schmidli et al [14] and some ideas in Gerss and Köpcke [15].

The paper is organized as follows. We first describe the statistical methodology, then illustrate the design using data from an FDA approved drug, and conclude with a discussion.
Methods

Hierarchical models

Hierarchical models (HM) are widely used when data are available from more than one trial. The models have two components: a data model and a parameter model. Data $Y_j$ from trial $j = 1, \ldots, J$ follow a distribution $F$ parameterized by trial-specific parameters $\theta_j$

$$Y_j|\theta_j \sim F(\theta_j) \quad (1)$$

and trial parameters $\theta_j$ follow a distribution $G$

$$\theta_j|\eta \sim G(\eta) \quad (2)$$

Inference for trial parameters can be done in a classical or Bayesian way. The simplest hierarchical model assumes (approximately) normal data. Often, the $Y_j$ are parameter estimates rather than individual data. For this case, the normal-normal hierarchical model (NNHM) is widely used:

$$Y_j|\theta_j \sim N(\theta_j, s_j^2) \quad (3)$$

and

$$\theta_j|\mu, \tau \sim N(\mu, \tau^2) \quad (4)$$

For fixed standard errors $s_j$ and known (assumed) $\tau$, classical and Bayesian conclusions for $\mu$ and trial parameters $\theta_j$ are the same if a non-informative (improper) prior for $\mu$ is used. For precision (inverse-variance) weights $w_j$, total precision $w_+$, and shrinkage parameters $B_j$

$$w_j = \frac{1}{s_j^2 + \tau^2}, \quad w_+ = \sum_{j=1}^{J} w_j, \quad B_j = \frac{s_j^2}{s_j^2 + \tau^2} \quad (5)$$

the posterior distribution of $\mu$ based on $Y = (Y_1, \ldots, Y_J)$ is

$$\mu|Y, \tau \sim N(\sum w_j Y_j / w_+, 1/w_+) \quad (6)$$

The posterior distributions of the trial parameters $\theta_j$ are

$$\theta_j|Y, \tau \sim N(B_j \hat{\mu} + (1 - B_j) Y_j, B_j(\tau^2 + B_j/w_+)) \quad (7)$$

where $\hat{\mu}$ is the posterior mean in (6). Classical analogues to the posterior means and standard deviations are maximum-likelihood estimates and their standard errors. The special cases of complete pooling and stratification arise for $\tau = 0$ and $\tau = \infty$, respectively.

Intermediate values of $\tau$ lead to different degrees of information sharing across trials, with the desirable properties one expects from an approach aiming to improve inference by borrowing information from similar trials:
• The hierarchical model shrinks the trial estimates towards the estimate of \( \mu \), which acts as a safeguard against over-interpreting extreme (good or bad) trial results. Shrinkage depends on trial size and between-trial heterogeneity. For large trials (small \( s_j \)), shrinkage is small, and notable shrinkage is only possible if \( \tau \) is of small to moderate size.

• The hierarchical model improves precision. Since

\[
B_j(\tau^2 + \frac{B_j}{w_+}) = s_j^2 - s_j^2B_j(1 - \frac{w_j}{w_+})
\]

the variance in (7) is always smaller than the variance \( s_j^2 \) of \( Y_j \).

**Between-trial heterogeneity**

The degree of between-trial heterogeneity (standard deviation \( \tau \) in (4)) for the parameters \( \theta_1, \ldots, \theta_J \) depends on the parameter scale and the outcome standard deviation \( \sigma \) for one observation unit (for example one subject or one event). Table 1 shows four typical heterogeneities and respective \( \tau \) values for \( \sigma = 2 \), which is often used as the reference standard deviation for normal approximations of binomial, count, and survival data [11]. For the four heterogeneities, Table 1 shows the range of parameter values expressed as the ratio between the 97.5% quantile and the median; for example, \( \tau = 1 \) implies a ratio of 7.1, which is clearly large and will be rare in practice.

For the common case of few trials, the size of between-trial heterogeneity is usually highly uncertain because \( \tau \) cannot be inferred well from the data. Therefore, it is important to use prior distributions covering plausible \( \tau \) values. Half-normal, half-Cauchy, and half-t distributions have been suggested in this context [11, 16, 17]. For the log-risk ratios used in the application, we will consider half-normal distributions [11] with scale parameters 0.5 and 1, which have medians (95%-intervals) equal to 0.34 (0.016,1.12) and 0.67 (0.031,2.24), respectively. Since \( \tau = 1 \) represents large heterogeneity, both priors are weakly informative, covering small to large heterogeneity and leaving small probabilities to unrealistically large heterogeneities, whereby the latter prior (with median 0.67) is rather conservative. For these priors, the 97.5% quantile to median ratio for risk ratio (RR) trial parameters is 2.98 and 8.89, respectively (see Appendix).

**Meta-analytic-predictive (MAP) prior**

When designing a new trial with parameter \( \theta_* \), the predictive distribution based on previous data \( Y_1, \ldots, Y_J \) constitutes the prior distribution for the new trial. This is known as the meta-analytic-predictive (MAP) prior [11, 12, 14]

\[
\theta_*|Y_1, \ldots, Y_J
\]
For the NNHM with known $\tau$

$$\theta_*|Y_1, \ldots, Y_J, \tau \sim N(\hat{\mu}, \tau^2 + 1/w_+)(10)$$

which follows from (7) by adding the new trial (with no data) to the model, i.e., $s_* = \infty$ and $B_* = 1$.

**Analysis for new trial**

Eventually, after the new data $Y_*$ have been observed, inference for $\theta_*$ can be done in two ways:

- **MAP** the meta-analytic-predictive (MAP) approach formally combines the prior (9) with $Y_*$ in a standard Bayesian way.

- **MAC** the meta-analytic-combined (MAC) approach does not require a prior distribution for $\theta_*$. It simply infers $\theta_*$ at the end of the new trial by a meta-analysis of historical and new data, resulting in

$$\theta_*|Y_1, \ldots, Y_J, Y_* (11)$$

Importantly, MAC and MAP give identical results [14]. The MAP approach is technically more involved because MAP priors (9) do not follow standard distributions and are typically heavy-tailed. This complicates the Bayesian analysis with $Y_*$ at the end of the trial, which can be addressed via mixture approximations [14]. However, even if a MAC analysis will usually be the method of choice and easy to perform with meta-analytic software, the MAP prior plays an important role: it quantifies prior information at the design stage, which may be required in the trial protocol.

**Effective sample sizes**

In many applications, the appropriate use of prior information will lead to smaller trials. The amount of information is ideally expressed as an equivalent approximate prior effective sample size (ESS). In our setting we are interested in $ESS_*$, the prior effective sample size of the MAP prior (9). Various approaches to ESS have been proposed [12, 18, 19, 20, 21]; they are similar in the sense that they relate the ESS to the precision (inverse of variance) of the prior distribution.

Here, we will use an approximate two-variances approach which requires: the variance $V_*$ of the analysis of interest, for which the $ESS_*$ is unknown; and, the variance $V_0$ of a simpler analysis (e.g. a meta-analysis with $\tau = 0$) with known $ESS_0$. Assuming that effective sample sizes are approximately proportional to precisions, the ESS of interest is

$$ESS_* = ESS_0 \times \frac{V_0}{V_*} (12)$$
In our case, \( V_\star \) will be variance of the MAP prior (9), whereas \( V_0 \) will be the one from the analysis assuming no between-trial heterogeneity \((\tau = 0)\).

**Case Study**

We now illustrate a design which utilizes phase II data for the design and analysis of a phase III study. The design relies on the methodology of Section 2 and additional considerations such as practical feasibility and regulatory requirements. Data from three phase II and one phase III trial on Zirgan (0.15% gel) for the treatment of acute herpetic keratitis will be used in the case study. All analyses were conducted in R [22] with the package bayesmeta [23] (see Appendix for code).

**Background**

Herpetic keratitis is an inflammatory condition of the eye caused by an outbreak of the herpes simplex virus (HSV) [24, 25]. It can have serious consequences and remains the leading cause of corneal blindness in the industrialized world [26, 27]. With as few as 1.5 million people affected world-wide [28], it has been classified as an orphan indication by the FDA [29] and the European Medical Agency [30].

In 2009, the FDA approved Zirgan for the treatment of herpetic keratitis (dendritic ulcers) [31]. To discuss all details of the approval is beyond the scope of this application (see the publicly available documents [32]). However, a few points are noteworthy. Most importantly, from the files [29, 32] it appears that approval was based on a retrospective analysis of the four relevant studies, three phase II and one phase III study. Retrospective means that the sponsor submitted the results of the studies after they were conducted, rather than seeking the agency’s advice beforehand. Subsequently, this led to discrepancies between the sponsor’s and FDA’s primary analyses, including changes of the population, of the endpoint and from superiority to non-inferiority.

The reasons behind this rather unusual approach to approval are not entirely clear. One explanation may be that the original manufacturer (Théa of France) did not intend to bring Zirgan to the US market on its own; rather, it sold the license for the US market to Sirion Therapeutics in 2007 which then initiated the submission. This and the fact that the clinical studies were already conducted in the 1990s may explain why no early discussions with the FDA took place.
Our goal here is not to reconstruct the approval history in detail. Rather, we will use the example to discuss an alternative, more efficient statistical approach towards approval, based on the following design specifications in the non-inferiority setting: cure rate at day 14 as endpoint, dendritic and geographic ulcers as population, and an absolute non-inferiority margin of 12 percentage points. Furthermore, we will use the risk ratio (RR) to quantify the treatment effect.

In the following, we present the evidence available at the hypothetical end-of-phase II meeting, a potential phase III trial and approval strategy, and the results of the actual phase III trial.

**Hypothetical end-of-phase II meeting**

Three randomized phase II studies [33] were conducted between April 1990 and October 1992 (Table 2). The studies were similar, with the only minor difference being the treatment regimen in study 6. For simplicity, we assume that this difference is not relevant for the clinical outcome.

We now turn the clock back and assume we are in the situation of an end-of-phase II meeting. We assume that the sponsor would agree to a non-inferiority analysis of Zirgan versus Acyclovir (the standard of care) with the primary endpoint being cure rate at day 14. Actually, setting a non-inferiority margin proved to be difficult. For cure rate at day 14, the FDA determined two effect sizes M1 [34]: 14% and 18% [32]. The latter implies an absolute non-inferiority margin of 12 percentage points when retaining one third of the effect. We assume here that this margin had been agreed to.

At this stage, it is interesting to perform a non-inferiority analysis (Zirgan versus Acyclovir) of the phase II data. If the evidence were overwhelming, it would be fair to ask whether a phase III study were required, or if approval could be granted based on the phase II data only.

Our interest is the phase III treatment effect. However, since no phase III data are available yet, the phase III treatment effect corresponds to the predicted treatment effect \( \theta^* \) from the phase II studies (see Section 2). The underlying statistical model is the NNHM (3), (4), with study-specific estimates of the log-risk-ratios \( Y_j = \log(\text{RR}_j) \) and standard errors

\[
s_j = \sqrt{1/r_C - 1/n_C + 1/r_T - 1/n_T}
\]

where \( n \) and \( r \) denote the number of patients and responders. This requires a
transformation to the risk difference scale and a sensible prior distribution for
the between-trial heterogeneity parameter \( \tau \) (the prior for \( \mu \) will be
non-informative).

The first point is straightforward. For a response rate \( p_C \) in the control group
and a pre-defined non-inferiority margin \( m = p_C - p_T \), the transformation is
given by the definition of the risk ratio; for \( p_C = 0.9 \) (the assumed cure rate
for Acyclovir based on historical data) and margin \( m = 0.12 \), non-inferiority
holds if \( RR_{T:C} \geq 0.867 \).

For the \( \tau \) prior we use \( \tau \sim HN(0.5) \), which has median 0.34 and 95% interval
(0.016;1.12). This prior is centered at moderate to substantial heterogeneity
and covers small to large heterogeneity (see Table 1). Notably, one may
perform a sensitivity analysis using a prior which favors larger between-trial
heterogeneity, e.g. \( \tau \sim HN(1) \).

The meta-analysis of the phase II data is shown in Figure 1, where the data,
study-specific (stratified) risk ratios \( RR_j \), the population mean \( \mu \) and the
predicted effect \( \theta^\star \) are shown. The reference line is drawn at the non-inferiority
margin (\( RR_{T:C} = 0.867 \) for \( p_C = 0.9 \)). The posterior for \( \tau \) indicates small
between-trial heterogeneity, with median 0.12 (95% interval 0.00 to 0.51).

The meta-analysis provides evidence for non-inferiority. If \( \mu \) were the
parameter of interest, an almost conclusive statement would follow: the lower
bound of the 95% interval is just below the non-inferiority margin. In fact,
\( P(\mu \geq \log(0.867)) = 97.1\% \), very close to 97.5%. However, the parameter \( \theta^\star \) in
the phase III trial is of interest. For this parameter, the evidence for
non-inferiority is weaker, but still substantial: \( P(\theta^\star \geq \log(0.867)) = 92.0\% \).

**Phase III study and proposed strategy for approval**

Designing a phase III study that allows to assess non-inferiority in
combination with the available evidence is desirable. Not only will this allow
to run a smaller study, it will also provide a treatment effect estimate based on
all relevant evidence. However, regulators may have good reasons to argue
that a smaller study may provide insufficient information for approval,
especially to assess the safety and risk/benefit ratio.

We now discuss the design of a phase III study (study 7) which uses phase II
data and allows for seeking approval based on an interim analysis. Depending
on negotiations with regulators, a post-approval commitment to run the study
to its end (even if approval is granted at interim) may be required. However, such negotiations will always be case-specific, highlighting the importance of early discussions with regulators. Nevertheless, the option to seek approval based on a positive interim analysis seems attractive for this case study. Since the endpoint is evaluated at day 14, there will be a small time window between the last patient enrolled for the interim analysis and the actual data read-out and analysis. With an anticipated recruitment period of two years, such a strategy could result in a markedly earlier approval.

When seeking approval based on interim results, the information fraction for the interim analysis becomes a key design aspect. We will assume that the interim analysis is conducted after 50% of the patients have been evaluated. For the sample size, in order to align with the actual study as originally conducted, we will assume \( n_C = n_T = 80 \). This results in interim sample sizes \( \tilde{n}_C = \tilde{n}_T = 40 \).

It is also important to understand how much phase II information is borrowed (which depends on the between-trial heterogeneity) when inferring the phase III effect. Using the variance ratio approach (Section 2), the ESS is 14.

**Operating characteristics**

We evaluate the operating characteristics (type I error rate and power) of the design and compare them to a phase III design ignoring the phase II data. The operating characteristics are presented in Table 3 based on 10'000 simulations conducted in \( R \) [22] with the package `bayesmeta` [23]. For different response rates \( p_C \) and treatment differences \( \delta \), two probabilities are shown: the probability to be successful at the final analysis (regardless of the outcome of the interim analysis), and the probability to be successful both at the interim and the final analysis.

The gain in power for the proposed design can be substantial. For example, for \( p_C = 0.7 \) (the Acyclorivr cure rate observed in phase II) and \( \delta = 0.06 \), the power is 87% versus 66%. The power gain is even larger at interim (70% versus 35%). When \( p_C = 0.9 \) (the observed cure rate for Acyclovir based on historical data) and \( \delta = 0 \), the power is 87% versus 79%, and 68% versus 48% at interim. The larger increase in power at interim is remarkable and due to the highly consistent phase II results, which suggested superiority of Zirgan.

The gain in power, however, comes at the price of an increased type I error rate. Strict type I error rate control cannot be guaranteed [35]. For example, for \( p_C = 0.7 \) and \( p_C = 0.9 \), the type I error rates are 6% versus 1% and 8%.
versus 3%. This increase is not dramatic, yet it cannot be ignored and needs to be discussed with regulators during the design phase. If it is of concern, robust prior distributions could be considered [14].

**Actual phase III data and analysis**

The actual data observed in the phase III study are only available for the final analysis. In order to reconstruct an interim analysis using half of the patients, we use an interim sample size of 40 per arm. Furthermore, we choose the number of responders such that observed response rate at interim is close to the observed response rate at the final analysis (see Figure 2).

The results are presented in Figure 2. The interim analysis based on all data (meta-analysis) allows to declare non-inferiority. Note that non-inferiority is claimed based on the parameter corresponding to study 7 ($\theta_7$) incorporating the evidence from studies 4, 5 and 6. On the other hand, the evidence from the phase III study alone is insufficient to declare non-inferiority at interim because the 95% interval includes the non-inferiority margin.

As mentioned before, the idea would be to gain approval with the interim phase III data supported by phase II via the meta-analysis, assuming other data (such as safety) is also favorable. Yet, depending on negotiations with regulators, the study may still run to its end, allowing a more robust evaluation of the effect at the final analysis. The results for the final analysis are also shown in Figure 2. For the meta-analysis, the interval for the risk ratio becomes narrower and still excludes the non-inferiority margin, thus confirming the interim result. The analysis using the phase III study leads to a lower bound of the interval (0.870) which is just above the non-inferiority threshold 0.867, also allowing to conclude non-inferiority.

Finally, results for $\tau$ indicate small between-trial heterogeneity at the interim and the final analysis. The posterior median (95% interval) is 0.12 (0.00 to 0.41) for the interim and 0.13 (0.00 to 0.43) for the final analysis. This supports the consistency of the results across all studies.

**Discussion**

Here we presented a simple, yet attractive design in rare diseases using phase II data in phase III studies. We illustrated it for binary endpoints, but the extension to other endpoints is straightforward.
The proposed approach uses the phase II data prospectively, which has obvious advantages. First, fewer patients are required in the phase III study. Second, the estimate combines all available evidence. And third, due to the nature of the approach, extreme results will be pulled towards the population mean. The Zirgan case study used to illustrate the design is built on real data as submitted to the FDA. However, the FDA approved Zirgan for a different indication (dendritic ulcers only) and endpoint (cure rate at day 7) than those used in our case study.

Of course, as with any design, all stakeholders need to be convinced. It may be argued that the case study is quite atypical since phase II studies are often not randomized in orphan diseases. This, however, becomes a self-fulfilling prophecy: if evidence from randomized phase II studies is only considered supportive, there is little motivation to perform them. On the other hand, if data from randomized phase II studies could be used, this would make them more attractive. It is therefore important that patient groups, regulators and sponsors consider such designs.

Other designs have been proposed before, and an excellent overview is given in Korn et al [36]. Some have been implemented in practice, for example the historical control monotherapy design proposed by French et al [37]. This design was used successfully, resulting in the approval of Aptiom (eslicarbazepine acetate) for the treatment of partial-onset seizures [38, 39]. Other examples include N-of-1 trials [40], global studies [41], or basket trials, e.g. the B2225 study for Imatinib [42].

It is also worth mentioning that recent initiatives to improve the drug development process send encouraging signals that a better use of the evidence is welcomed. Important directions are given in the 21st Century Cures Act [8], which encourages the FDA to further evaluate the use of Bayesian methodology and non-randomized evidence. Furthermore, calls have been made to make the drug approval process more continuous and flexible to account for evidence as it accumulates [43]. The European Medicines Agency has also initiated various working groups.

It is clear that we only considered a small portion of the drug approval process. Efficacy plays a unique role when seeking approval, but other measures are also important. Safety is critical, and additional evidence may be required to assess long-term risks. However, this can often be achieved as a post-approval requirement in the form of non-randomized open-label studies. This approach has the advantage that patients have early access to the treatment whilst additional data are collected.
The proposed approach has limitations. The potential increase in type I error needs to be considered and may require design modifications, including robust meta-analytic models [14]. Likewise, for a non-inferiority design, one may consider to directly model the risk difference and use a meta-analytic approach on this scale (e.g. Warn et al [44]). However, most applications will be superiority trials, for which relative measures such as risk ratios or odds ratios are common. Finally, we did not use historical data to inform the prior for the between-trial heterogeneity (τ), even though this would be possible [45].

The motivation of this paper was not to challenge FDA’s decision. On the contrary: only due to the many publicly available FDA documents, we were able to use this insightful example. We hope that it will facilitate the implementation of the proposed design in practice.
Declaration of Conflicting Interest

Dr. Wandel and Dr. Neuenschwander are employed by Novartis Pharma AG, Basel, Switzerland.
References

[1] Unkel S, Röver C, Stallard N et al. Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. *Orphanet J Rare Dis*. 2016;11:16.

[2] https://www.gpo.gov/fdsys/pkg/STATUTE-96/pdf/STATUTE-96-Pg2049.pdf (1983, accessed 18 July 2016).

[3] FDA. Rare diseases: common issues in drug development http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458485.pdf (accessed 20 June 2016)

[4] http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/2436-sc1-pm-08-2017.html

[5] Sharma A, Jacob A, Tandon M, and Kumar D. Orphan drug: Development trends and strategies. *J Pharm Bioallied Sci*. 2010; 2: 290-299.

[6] Sasinowski F. Quantum of effectiveness evidence in FDA’s approval of orphan drugs: cataloging FDA’s flexibility in regulating therapies for persons with rare disorders. *Drug Information Journal*. 2012;46:238-263.

[7] Sasinowski F, Panico E, Valentine J. Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs: Update, July 2010 to June 2014. *Therapeutic Innovation & Regulatory Science*. 2015;49:680-697.

[8] https://www.congress.gov/bill/114th-congress/house-bill/6 (2015, accessed 12 April 2016)

[9] Friede T, Röver C, Wandel S, Neuenschwander B. Meta-analysis of few small studies in orphan diseases. *Res Synth Methods*. 2016 (epub ahead of print).

[10] Friede T, Röver C, Wandel S, Neuenschwander B. Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases. *Biom J* (accepted).

[11] Spiegelhalter DJ, Abrams KR, and Myles JP. *Bayesian Approaches to Clinical Trials and Health-Care Evaluation*. 1st ed. Chichester: Wiley, 2004.

[12] Neuenschwander B, Capkun-Niggli G, Branson M, and Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. *Clin Trials* 2010; 7:5-18.
[13] Neuenschwander B, Roychoudhury S, Schmidli H. On the use of co-data in clinical trials. *Statistics in Biopharmaceutical Research* 2016.

[14] Schmidli H, Gsteiger S, Roychoudhury S, et al. Robust meta-analytic-predictive priors in clinical trials with historical control information. *Biometrics* 2014; 70:1023-32.

[15] Gerss JWO and Köpcke W. Clinical Trials and Rare Diseases. In: de la Paz MP and Groft SC (eds) *Advances in Experimental Medicine and Biology*, Springer 2010.

[16] Gelman A. Prior distributions for variance parameters in hierarchical models. *Bayesian Anal* 2006; 1:515-533.

[17] Polson NG and Scott JG. On the half-cauchy prior for a global scale parameter. *Bayesian Anal* 2012; 7:887-902.

[18] Malec D. A closer look at combining data among a small number of binomial experiments. *Stat Med* 2001; 20:1811-1824.

[19] Pennello G and Thompson L. Experience with reviewing Bayesian medical device trials. *J Biopharm Stat* 2008; 18:81-115.

[20] Morita S, Thall P, and Müller P. Determining the effective sample size of a parametric prior. *Biometrics* 2008, 64:595-602.

[21] Hampson L, Whitehead J, Eleftheriou D, Brogan P. Bayesian methods for the design and interpretation of clinical trials in very rare diseases. *Stat Med* 2014;33:4186-201.

[22] R Core Team. *R: A Language and Environment for Statistical Computing* https://www.R-project.org/

[23] Röver C. *bayesmeta: Bayesian random-effects meta-analysis* 2015 http://cran.r-project.org/package=bayesmeta

[24] Kaye S and Choudhary A. Herpes simplex keratitis. *Prog Retin Eye Res* 2006; 25:355-80.

[25] White ML and Chodosh J. Herpes Simplex Virus Keratitis: A Treatment Guideline. In: *Hoskins Centers Compendium of Evidence-Based Eye Care*, http://www.aao.org/clinical-statement/herpes-simplex-virus-keratitis-treatment-guideline (2014, accessed 18 January 2016).

[26] Dawson CR and Togni B. Herpes simplex eye infections: clinical manifestations, pathogenesis and management. *Surv Ophthalmol* 1976; 21:121-35.

[27] Suresh PS and Tullo AB. Herpes simplex keratitis. *Indian J Ophthalmol* 1999; 47:155-165.
[28] Farooq A and Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol. 2012; 57:448-62.

[29] FDA. Zirgan approval correspondence. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211s000_AdminCorres.pdf (2009, accessed 18 January 2016).

[30] European Medicines Agency. Public summary of opinion on orphan designation. Ciclosporin for the treatment of Herpes simplex virus stromal keratitis. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006041.pdf (2015, accessed 23 May 2016)

[31] FDA. Approval letter. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022211s000ltr.pdf (accessed 18 January 2016)

[32] FDA. Drug approval package: Zirgan 0.15%. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022211_zirgan_toc.cfm (accessed 18 January 2016)

[33] Chou TY and Hong BY. Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Ther Clin Risk Manag. 2014; 10:665-81.

[34] FDA. Guidance for industry: non-inferiority clinical trials http://www.fda.gov/downloads/Drugs/.../Guidances/UCM202140.pdf (accessed 25 May 2016)

[35] Viele K, Berry S, Neuenschwander B, et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014;13:41-54.

[36] Korn EL, McShane LM, Freidlin B. Statistical challenges in the evaluation of treatments for small patient populations. Sci Transl Med. 2013;5:178sr3

[37] French JA, Wang S, Warnock B, Temkin N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia. 2010;51:1936-43

[38] FDA. Aptiom approval letter. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022416Orig1s001ltr.pdf (2009, accessed 12 April 2016).

[39] FDA. Aptiom label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022416s001lbl.pdf (2009, accessed 12 April 2016).

[40] Guyatt G, Sackett D, Taylor W et al. Determining Optimal Therapy Randomized Trials in Individual Patients. N Engl J Med 1986; 314:889-892
[41] Kuerner T. Essential rules and requirements for global clinical trials in rare lung diseases: a sponsor’s standpoint. *Respir Investig*. 2015;53:2-6.

[42] Heinrich MC, Joensuu H, Demetri GD et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. *Clin Cancer Res*. 2008;14:2717-25

[43] Roy ASA. Stifling new cures: the true cost of lengthy clinical drug trials. *Project FDA Report No. 5*, Manhattan Institute.

[44] Warn D, Thompson S, Spiegelhalter D. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. *Stat Med*. 2002;21:1601-23.

[45] Turner R, Jackson D, Wei Y et al. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. *Stat Med*. 2015;34:984-98.
Tables

Table 1: Classification of between-trial heterogeneity with 97.5% quantile to median ratio for risk ratio (RR) trial parameters; σ is the outcome standard deviation, τ is the between-trial standard deviation.

| heterogeneity (σ/τ) | τ (if σ = 2) | RR_{97.5%}/RR_{50%} |
|---------------------|-------------|----------------------|
| large (2)           | 1           | 7.10                 |
| substantial (4)     | 0.5         | 2.66                 |
| moderate (8)        | 0.25        | 1.63                 |
| small (16)          | 0.125       | 1.28                 |
| Study (Phase) | 4 (II) | 5 (II) | 6 (II) | 7 (III) |
|--------------|--------|--------|--------|---------|
| **Objective** | Efficacy & Safety | Efficacy & Safety | Efficacy & Safety | Efficacy & Safety |
| **Design** | 3-arm randomized | 2-arm randomized | 3-arm randomized | 2-arm randomized |
| **Location** | Africa | Europe | Pakistan | Europe & Africa |
| **Product** | G: 0.15%, 0.05%; A: 3% | G: 0.15%; A: 3% | G: 0.15%, 0.05%; A: 3% | G: 0.15%; A: 3% |
| **Regimen** | 1 | 1 | 2 | 1 |
| **Study period (months)** | 4/90–5/92 (25) | 12/90–5/92 (18) | 5/91–10/92 (18) | 9/92–9/94 (25) |
| **Total cure rate, day 14 (%)** | Zirgan: 19/23 (82.6) | Acyclovir: 16/22 (72.7) | 15/18 (83.3) | 12/17 (70.6) | 31/36 (86.1) | 27/38 (71.1) | 74/84 (88.1) | 73/80 (91.3) |

Regimen: 1 = 1 drop 5x/day until ulcer healed, then 1 drop 3x/day for 7 days; 2 = 1 drop 5x/day for 10 days
Table 3: Operating characteristics for phase II/III (meta-analysis) and phase III alone

| pc   |  0.7 | 0.75 | 0.80 | 0.85 | 0.90 |
|------|------|------|------|------|------|
|      | 0.12 | 0.06 | 0.0  | 0.06 | 0.12 |
| 6 (3)| 25 (15)| 56 (39)| 87 (70)| 98 (90)| 0.70 |
| 1 (0)| 0.75 |
| 7 (4)| 26 (16)| 61 (44)| 91 (75)| 100 (94)| 0.75 |
| 1 (0)| 0.80 |
| 7 (4)| 29 (18)| 68 (49)| 94 (80)| 100 (97)| 0.80 |
| 2 (1)| 0.85 |
| 7 (4)| 32 (19)| 76 (55)| 98 (88)| 100 (100)| 0.85 |
| 3 (1)| 0.90 |
| 8 (4)| 38 (24)| 87 (68)| 100 (98)| – | 0.90 |
| 3 (1)|      |

Percentages presented: probability for success at final (probability for success at interim and final). The first row corresponds to the meta-analysis, the second row to the analysis of the phase III study alone.
Figures

Figure 1: Data and results at end-of-phase II meeting

| Study | $r_T/n_T$ | $r_C/n_C$ | Risk Ratio |
|-------|----------|----------|------------|
| Study 4 | 19/23 | 16/22 | 1.14 [0.83, 1.56] |
| Study 5 | 15/18 | 12/17 | 1.18 [0.82, 1.71] |
| Study 6 | 31/36 | 27/38 | 1.21 [0.95, 1.54] |
| Population effect exp($\mu$) | | | 1.18 [0.85, 1.63] |
| Predicted effect exp($\theta$) | | | 1.18 [0.65, 2.13] |
Figure 2: Data and results for interim and final analysis in Phase III
Appendix

library("bayesmeta")
library("metafor")

################################################
# Part I - ratio of RRs for tau ~ HN(...)  
################################################
set.seed(314)
N <- 1000000
tau1 <- abs(rnorm(N, 0, 0.5))
tau2 <- abs(rnorm(N, 0, 1.0))
theta1 <- rnorm(N, 0, tau1)
theta2 <- rnorm(N, 0, tau2)
exp(quantile(theta1, prob = 0.975))
exp(quantile(theta2, prob = 0.975))

################################################
# Part II - application  
################################################
# --------------------------------------------
# read-in data
# transform into 2x2 cell entries
# derive mean and se from normal approximation
# --------------------------------------------
all.data <- data.frame(study = c("4", "5", "6", "7IA", "7FA"),
rt = c(19, 15, 31, 35, 74),
nt = c(23, 18, 36, 40, 84),
rc = c(16, 12, 27, 36, 73),
nc = c(22, 17, 38, 40, 80))
all.data$ai <- all.data$rt
all.data$bi <- all.data$nt - all.data$rt
all.data$ci <- all.data$rc
all.data$di <- all.data$nc - all.data$rc
nmappr <- escalc(ai=ai, bi=bi, ci=ci, di=di,
data=all.data,measure="RR")

# analyses:
# - end-of-phase-II
# - interim for phase III

24
# - final for phase III
# summaries:
# - population mean,
# - predicted effect for end-of-phase-II
# - phase-III effect for interim and final analyses
# ---------------------------------

eop2 <- bayesmeta(y = nmappr$yi[1:3], sigma = sqrt(nmappr$vi[1:3]),
  tau.prior = function(t){dhalfnormal(t, scale=0.5)})

ph3IA <- bayesmeta(y = nmappr$yi[1:4], sigma = sqrt(nmappr$vi[1:4]),
  tau.prior = function(t){dhalfnormal(t, scale=0.5)})

ph3FA <- bayesmeta(y = nmappr$yi[c(1:3,5)], sigma = sqrt(nmappr$vi[c(1:3,5)]),
  tau.prior = function(t){dhalfnormal(t, scale=0.5)})

round(exp(t(eop2$summary)[,c("median", "95% lower", "95% upper")]), 3)
round(exp(ph3IA$theta[,c("median", "95% lower", "95% upper"),4]), 3)
round(exp(ph3FA$theta[,c("median", "95% lower", "95% upper"),4]), 3)